prove HRQoL. Factors other than medications adherence should be focused in further studies to improve HRQoL.

PR2
A FEASIBILITY STUDY OF PREFERENCE-BASED HEALTH-RELATED QUALITY OF LIFE MEASURES ON PATIENTS WITH IRRItable BOWEL SYndrome IN TAIWAN
Hau CC1, Chen LC2, Wen YH1, Su YC1
1Kaohsiung Medical University, Kaohsiung, Taiwan, 2University of Nottingham, UK
OBJECTIVES: Irritable bowel syndrome (IBS) is a relapsing, chronic functional gastrointestinal disorder leading to long-term disturbances on health-related quality of life (HRQoL). Various functional and QoL measures have been developed to evaluate IBS outcomes, but none of the preference-based QoL measure has been applied and validated on Taiwanese people. This study aimed to explore the feasibility of applying preference-based HRQoL measures to IBS patients in Taiwan.

METHODS: This prospective study was conducted from July to December 2010 at gastroenterology clinics in a regional hospital in southern Taiwan. IBS outpatients diagnosed by Rome III criteria were invited to participate semi-structure interview survey by using EuroQol (EQ-SD) questionnaire, 100-mm visual analogue scale (EQ-SD VAS) and standard gamble (SG) method. The EQ-SD assessment was transformed into EQ-SD index using Japanese preference weight. Multiple regression was used to assess factors associated with utilities, e.g. demographic, socioeconomic status and disease severity.

RESULTS: Of all, 29 participants (mean age 45.8 ± 16.5 years, 62.1% female) completed QoL survey, except for one rejected SG survey for disagreeing with SG hypothesis. Participants’ IBS subtypes include constipation (n=11, 37.9%), diarrhea (n=16, 55.2%) and unsubtyped IBS (n=2, 6.9%). 12 (41.4%) participants were newly diagnosed IBS and 12 had over two-year disease history. Participants had no problem in EQ-SD survey, some experienced difficulties in dimensions of pain/discomfort and anxiety/depression. Mean utility derived from SG (0.85 ± 0.15) and EQ-5D VAS (0.79 ± 0.15) was significantly higher than results derived from EQ-SD and EQ VAS, and this finding matches previous literature. Further validate the utility measures in more IBS patients with various subtypes and severity is needed.

PR3
UTILITY VALUES FOR CHEMOTHERAPY-RELATED ADVERSE EVENTS: A REVIEW OF THE LITERATURE
Shabardin FN1, Chen LC2, Elliott RF3, Payne K1
1University of Malaya, Kuala Lumpur, Malaysia, 2University of Nottingham, UK, 3University of Manchester, Manchester, UK
OBJECTIVES: Chemotherapy offers cancer patients the potential benefits of improved mortality and morbidity but may cause detrimental outcomes due to adverse drug events (ADEs) that could require time-consuming, resource-intensive and costly clinical management. To appropriately assess chemotherapy agents in an economic evaluation, the impact of ADEs could be included in terms of their incidence, costs of their management and valuation of the perceived disbenefits via (dis)utility of ADEs. This review aimed to identify published studies reporting utility values for chemotherapy-related ADEs. METHODS: A structured electronic search was performed for utility, utility valuation methods and generic terms for cancer treatment was conducted in MEDLINE and EMBASE in June 2011. Inclusion criteria were: 1) primary data, and 2) elicitation of utility chemotherapy-related ADE. Two reviewers identified studies and extracted data independently. Any disagreements were resolved by a third reviewer. RESULTS: Eighteen studies met the inclusion criteria from the 853 abstracts initially identified, collectively reporting 218 utility values for chemotherapy-related ADEs. All eighteen studies used short descriptions (vignettes) to obtain the utility values. Of the 218 utility values, 178 were elicited using SG or TTO while 40 were elicited using VAS. There were 169 utility values of specific chemotherapy-related ADEs (with the top ten being anemia (34 values), nausea and/or vomiting (32 utility values), neuropathy (21 values), neutropenia (12 values), diarrhea (12 values), stomatitis (10 values), fatigue (8 values), alopecia (7 values), hand-foot syndrome (5 values) and skin reaction (5 values)) and 49 of non-specific chemotherapy-related adverse events.

CONCLUSIONS: This study has summarised the current evidence base of utility values for chemotherapy-related ADEs. Only 178 of the 218 values were elicited using choice-based methods (SG & TTO) and therefore could potentially be used as parameter inputs in an economic evaluation incorporating ADEs of a chemotherapeutic agent.

PR4
THE EFFECT OF NEUROPATHIC PAIN ON HEALTH STATUS, WORK PRODUCTIVITY LOSS, AND HEALTH CARE RESOURCE USE IN JAPAN
D*Bonavenunta MD1, Fukuda Y2, Stanikzai A1
1Kantar Health, New York, NY, USA, 2National Institute of Public Health, Suita, Japan, 3Kantar Health, Princeton, NJ, USA
OBJECTIVES: The current study is to quantify the burden of neuropathic pain (NeP) with respect to health status, work productivity loss, and health care resource utilization among patients in Japan. METHODS: The 2010 Japan National Health and Wellness Survey (NHWS), a self-reported, Internet-based survey of adult Japan population, was used as the data source for this study (N=25,000). All respondents were categorized as those reporting either NeP, a form of pain other than NeP, and no pain. These groups were compared on health status (using the SF-12v2), work productivity loss (using the WPAI), and health care resource use (provider visits, hospitalizations, and emergency room (ER) visits) in the past six months using regression modeling controlling for demographics, health behaviors, and comorbidities. RESULTS: Of the 25,000 patients in Japan, 0.23% (n=58) reported experiencing NeP, 5.57% (n=1392) reported experiencing another form of pain, and 94.20% reported experiencing no pain in the past month. Adjusting for covariates, patients experiencing NeP reported significantly worse physical and mental component summary scores (42.43 and 41.60, respectively) than patients experiencing another form of pain (45.41 and 44.83, respectively) and patients without pain (51.03 and 47.41, respectively) (all p<.05). A similar pattern was observed for health utilities (0.69 vs. 0.66 vs. Other patients). Overall work impairment was similar between those with NeP and those with other pain (26.50% vs. 26.63%, respectively, p>.21); however, patients with NeP reported greater overall work impairment than those without pain (26.50%, p<.05). Patients with NeP also reported significantly more provider visits (18.85) than those with other pain (2.21) and no pain (4.60) (all p<.05). CONCLUSIONS: Patients in Japan with NeP report significantly worse humanistic and economic outcomes compared with those with no pain and even other forms of pain. The results suggest improved management of NeP may have substantial health outcome benefits.